Retatrutide
Neutral, BioHarmony verdict
BioHarmony score 5.6 out of 10
Retatrutide is Lilly's investigational once-weekly GLP-1/GIP/glucagon triple agonist. Jastreboff 2023 reported up to 24.2% body-weight loss at 48 weeks, but FDA says retatrutide is not approved and cannot legally be compounded.
Read full reportWhat is Retatrutide?
Retatrutide is an investigational once-weekly peptide drug from Eli Lilly that activates three metabolic hormone receptors at once: GLP-1R, GIPR, and glucagon receptor. In practice, that means appetite suppression, improved insulin signaling, and a glucagon-driven push toward hepatic fat oxidation and thermogenesis in the same molecule. This is why retatrutide sits beyond semaglutide and tirzepatide in pharmacological ambition.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Simultaneous agonism of GLP-1, GIP, and glucagon receptors; the glucagon arm is intended to raise hepatic fat oxidation and energy expenditure while GLP-1/GIP constrain appetite and improve glycemia.
Safety watch-outs
- Persistent vomiting or dehydration
- Severe abdominal pain
- Blood in stool or black stool
- Symptoms of pancreatitis: severe upper abdominal pain radiating to back
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for Retatrutide yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (3)
Attributed viewpoints, separate from primary research.
- My Top Peptide Stack for Mental Clarity & Muscle Repair Alex Kikel,
- May 2026 Q&A | Retatrutide, Testosterone, Autoimmune, and Beyond Hunter Williams,
- Retatrutide Diarrhea: Why It Happens and How to Stop It Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.
Primary sources
- FDA's concerns with unapproved GLP-1 drugs used for weight loss U.S. Food and Drug Administration,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.